Evidence map›Paper›PMID 41724916›Full record

ArticleAnnals of surgical oncology2026

Evaluation of Talimogene Laherparepvec for the Treatment of Advanced Nonmelanoma Skin Cancers.

J Slatton, V Jiminez, J Beam, N Rademacher, K Montgomery, S Bateni, K Broman

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

J SlattonHeersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
V JiminezHeersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
J BeamHeersink School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
N RademacherDepartment of Surgery, University of Alabama at Birmingham, Birmingham, AL, USA.
K MontgomeryDepartment of Surgery, University of Alabama at Birmingham, Birmingham, AL, USA.
S BateniDepartment of Surgery, University of Alabama at Birmingham, Birmingham, AL, USA.
K BromanDepartment of Surgery, University of Alabama at Birmingham, Birmingham, AL, USA. kkbroman@mdanderson.org.ORCID http://orcid.org/0000-0002-4679-4665

Funding

DEEP SOUTH TRANSLATIONAL RESEARCH MENTORED CAREER DEVELOPMENT PROGRAMKL2TR003097 · NCATS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI SAAG, KENNETH G · 2019 to 2023
$5.2M
Leveraging Health Systems to Increase Implementation of Evidence-Based Surgical Cancer CareK08CA283001 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BROMAN, KRISTY KUMMEROW · 2023 to 2025
$592k
NCATS NIH HHS KL2 TR003097NCI NIH HHS K08CA283001
6 · The paper itself

Abstract

introductionTalimogene laherparepvec (T-VEC) is an intralesional, injectable oncolytic herpes virus that is FDA-approved to treat Stage III-IV melanoma. The utility of T-VEC for nonmelanoma skin cancers (NMSC), including Merkel cell carcinoma (MCC) and squamous cell carcinoma (SCC), as well as its use with concurrent immune therapy (IO), is poorly defined. The purpose of this study is to evaluate outcomes of T-VEC for MCC and SCC with and without concurrent immune therapy.

methodsThis retrospective study included patients at a single institution with MCC or SCC and treated with T-VEC between May 2016 and May 2023. Abstracted cohort data were reported using descriptive statistics.

resultsTen MCC and three SCC patients were eligible. Four MCC patients and all three SCC patients received concurrent pembrolizumab. Overall, six patients achieved complete response (CR), one had partial response (PR), and six had progressive disease (PD). Of the six patients who achieved CR, two recurred at 8 and 56 months. Those without recurrence had a durable response at a median follow-up of 25 months.

conclusionsOur initial experience with a small, single-institution cohort demonstrated tumor response to intralesional T-VEC with or without immunotherapy in some patients with NMSC. Nearly 50% of participants had a complete response; two-thirds of responders remained relapse-free at the time of follow-up. Some observed responses are not attributable to T-VEC alone due to high usage rates of IO. Future work should expand to larger cohorts and focus on its use with and without immune therapy.

Indexed as

Antineoplastic Agents, ImmunologicalBiological ProductsCarcinoma, Merkel CellCarcinoma, Squamous CellOncolytic VirotherapySkin NeoplasmsAgedAged, 80 and overAntibodies, Monoclonal, HumanizedCombined Modality TherapyCutaneous Squamous Cell CarcinomaFemaleFollow-Up StudiesHerpesvirus 1, HumanHumansMaleAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalBiological Productspembrolizumabtalimogene laherparepvecNon-melanoma skin cancerOncolytic virus therapyOutcomes researchRetrospective cohortTalimogene laherparepvec

Identifiers

PMID41724916
PMCPMC13179203

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.